Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men.
A randomized, double-blind clinical trial of plasma-derived and DNA recombinant hepatitis B virus vaccines was conducted in 186 homosexual men. Nine months after the immunization series (three doses) began, the seroconversion rate in the plasma vaccine group was 88% (68/77); this was significantly higher than the 74% (60/81) response rate of the recombinant vaccine group. Men positive for antibody to the human immunodeficiency virus (HIV) had a considerably higher nonresponse rate to either vaccine than expected in non-HIV-infected homosexual men. The odds ratios of nonresponse to hepatitis B virus vaccine for HIV-seropositive vs HIV-seronegative subjects were 12.0 (95% confidence interval, 1.7 to 89.3) and 13.6 (95% confidence interval, 2.3 to 148.3) for the plasma and DNA recombinant vaccines, respectively.
Odaka
N
N
Johns Hopkins University School of Hygiene and Public Health, Baltimore, Md 21205.
Eldred
L
L
Cohn
S
S
Muñoz
A
A
Fields
H A
HA
Fox
R
R
Solomon
R
R
Kaslow
R
R
Polk
B F
BF
D000328:Adult; D000367:Age Factors; D004311:Double-Blind Method; D006679:HIV Seropositivity / Q000276:immunology; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000276:immunology*; D006716:Homosexuality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines